These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 2059880

  • 1. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis.
    Aicardi G, Milani S, Imbimbo B, Vignolo M, Di Battista E, Gusmano R, Terragna A, Cordone G, Cottafava F, Coppo R.
    Calcif Tissue Int; 1991 Apr; 48(4):283-7. PubMed ID: 2059880
    [Abstract] [Full Text] [Related]

  • 2. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
    Aicardi G, Benso L, Vignolo M, Terragna A, Verrina E, Cordone G, Coppo R, Sernia O, Sardella ML, Di Battista E.
    Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Deflazacort induced stronger immunosuppression than expected.
    Gonzalez-Castañeda RE, Castellanos-Alvarado EA, Flores-Marquez MR, Gonzalez-Perez O, Luquin S, Garcia-Estrada J, Ramos-Remus C.
    Clin Rheumatol; 2007 Jun; 26(6):935-40. PubMed ID: 16738843
    [Abstract] [Full Text] [Related]

  • 7. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
    Olgaard K, Storm T, van Wowern N, Daugaard H, Egfjord M, Lewin E, Brandi L.
    Calcif Tissue Int; 1992 Jun; 50(6):490-7. PubMed ID: 1525702
    [Abstract] [Full Text] [Related]

  • 8. Experience with deflazacort in children and adolescents after renal transplantation.
    Schärer K, Feneberg R, Klaus G, Paschen C, Wüster C, Mehls O, Schaefer F.
    Pediatr Nephrol; 2000 Jun; 14(6):457-63. PubMed ID: 10872183
    [Abstract] [Full Text] [Related]

  • 9. Potency ratio--a brief synopsis.
    Avioli LV.
    Br J Rheumatol; 1993 May; 32 Suppl 2():24-6. PubMed ID: 8495276
    [Abstract] [Full Text] [Related]

  • 10. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
    Scudeletti M, Puppo F, Lanza L, Mantovani L, Bosco O, Iudice A, Imbimbo B, Indiveri F.
    Eur J Clin Pharmacol; 1993 May; 45 Suppl 1():S29-34. PubMed ID: 8313931
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM.
    Neurology; 2016 Nov 15; 87(20):2123-2131. PubMed ID: 27566742
    [Abstract] [Full Text] [Related]

  • 12. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
    Cacoub P, Chemlal K, Khalifa P, Wechsler B, De Gennes C, Belmatoug N, Cohen P, Ziza JM, Verdoncq B, Piette JC.
    J Rheumatol; 2001 Nov 15; 28(11):2474-9. PubMed ID: 11708421
    [Abstract] [Full Text] [Related]

  • 13. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
    Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, Cnaan A, McDonald CM, CINRG Investigators.
    Neurology; 2015 Sep 22; 85(12):1048-55. PubMed ID: 26311750
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
    Morabito F, Callea I, Irrera G, Cartisano G, Dattola A, Rodinò A, Brugiatelli M.
    Eur J Haematol; 1997 May 22; 58(5):301-6. PubMed ID: 9222284
    [Abstract] [Full Text] [Related]

  • 17. Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.
    Balsan S, Stéru D, Bourdeau A, Grimberg R, Lenoir G.
    Calcif Tissue Int; 1987 Jun 22; 40(6):303-9. PubMed ID: 3111667
    [Abstract] [Full Text] [Related]

  • 18. Differential effect of glucocorticoids on calcium absorption and bone mass.
    Gennari C.
    Br J Rheumatol; 1993 May 22; 32 Suppl 2():11-4. PubMed ID: 8495275
    [Abstract] [Full Text] [Related]

  • 19. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
    Campbell C, Jacob P.
    BMC Neurol; 2003 Sep 08; 3():7. PubMed ID: 12962544
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
    Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL.
    Neuromuscul Disord; 2012 Dec 08; 22(12):1046-56. PubMed ID: 22967789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.